The invention relates to novel 18-norsteroids (gonatrienes) of general formula
(I), wherein R1, R2, R3, R6, R7,
R8, R9, R11, R11, R14,
R15, R15, R16, R17 and R17
have the meaning cited in the description, and to the use of said compounds as
pharmaceutical active ingredients. Said compounds exhibit a high affinity in vitro
for estrogen receptor preparations of rat prostate and in an estrogen receptor
preparation of rat uterus. Said compounds exhibit in vivo preferential activity
on bones as compared to the uterus and/or significant activity with regard to stimulating
the expression of 5HT2a-receptors and transporter molecules. The invention also
relates to the production of said compounds, therapeutic use and galenic form of
said compounds contained in the novel compounds of invention. The invention also
relates to utilization of steroids based on the gonatriene molecular skeleton in
order to treat estrogen deficiency-induced diseases and disorders, in addition
to the use of said gonatriene structural component in the total structure of compounds
which dissociate to produce enhanced estrogen activity in bone as compared to the
uterus
##STR1##
